What question did this study set out to answer?

To evaluate the efficacy of tranexamic acid (TXA) in reducing blood loss and transfusion needs during lower extremity endoprosthetic reconstruction for oncologic purposes.

April 18, 2026Open Access

View Full Paper

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

Key Points

To evaluate the efficacy of tranexamic acid (TXA) in reducing blood loss and transfusion needs during lower extremity endoprosthetic reconstruction for oncologic purposes.
Conducted a retrospective comparative study of 617 patients
Analyzed perioperative TXA use
Measured blood loss and postoperative transfusion requirements
Assessed thromboembolic complications
TXA use was linked to a significant reduction in blood loss
Postoperative transfusion requirements decreased
No detectable increase in thromboembolic complications was noted

Abstract

Perioperative TXA use was associated with reduced blood loss and postoperative transfusion requirements without a detectable increase in thromboembolic complications, supporting TXA as a beneficial adjunct in musculoskeletal oncology limb salvage procedures.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Chenard et al. (Wed,) studied this question.

synapsesocial.com/papers/69e3215140886becb65407fa https://doi.org/https://doi.org/10.1002/jso.70250

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper